IQVIA Holdings Inc. - IQV STOCK NEWS

IQVIA Holdings Inc. (NYSE: IQV) will release its fourth-quarter and full-year 2021 financial results on February 15, 2022, before the market opens. The management team will present a conference call at 9:00 a.m. Eastern Time on the same day. Interested participants can register in advance via the Investor Relations website. A replay of the event will be available two hours post conclusion. IQVIA is a leader in analytics and clinical research, supporting healthcare improvements across its operations in over 100 countries.

IQVIA has appointed Sheila A. Stamps to its board of directors, effective immediately. With over 40 years of experience in strategic governance and operational management, Ms. Stamps has held leadership roles in both public and private sectors, including as a senior investment advisor for the New York State Comptroller. She serves on boards of multiple public companies and has a strong background in audit and finance. Following her appointment, IQVIA's board comprises 11 directors, ten of whom are independent.

IQVIA (NYSE:IQV) has appointed Leslie Wims Morris to its board of directors, effective immediately. Wims Morris brings over 25 years of financial services experience, currently serving as Managing Director and Head of Corporate Development at JPMorgan Chase. Her expertise includes managing strategic partnerships and participating in firmwide initiatives. CEO Ari Bousbib expressed confidence that her global experience will add valuable insight to the company. Wims Morris holds an MBA from Harvard and a BA in English from Yale.

IQVIA (NYSE:IQV) has launched new Research Nursing and Phlebotomy services that enhance patient access and care during clinical trials. These services enable patients to receive professional care at home, improving outcomes and reducing costs. Ronan Brown, global head of Decentralized Trial Solutions, emphasized that this initiative reflects IQVIA's commitment to patient-centric research. The mobile workforce provides flexible support for clinical trials, enhancing patient experiences and protocol compliance while ensuring quality oversight and training. This innovation marks a significant step in decentralizing clinical trials.

IQVIA (NYSE:IQV) has launched a new module, Grants and Funding Management, within its Orchestrated Customer Engagement (OCE) solutions. This module aims to provide life sciences companies a comprehensive tool to manage their global strategic giving programs, from grant submission to payment processing. The automated system enhances user experience and compliance, helping to streamline workflows and reduce errors. IQVIA continues to leverage its expertise to adapt to evolving market needs, promoting efficiency in funding request management.

IQVIA reported impressive financial results for Q3 2021, with revenue reaching $3,391 million, a 21.7% year-over-year increase. GAAP Net Income soared to $261 million, marking a 158.4% rise. Adjusted EBITDA stood at $728 million, up 20.5%. The company raised its full-year guidance for revenue, Adjusted EBITDA, and Adjusted Diluted EPS. R&D Solutions contracted backlog grew 12.7% to $24.4 billion, with an expected $6.9 billion conversion to revenue in the next year. Overall, IQVIA demonstrated robust growth across all segments.

IQVIA Holdings Inc. (NYSE:IQV) will report its third-quarter 2021 financial results on October 21, 2021, before market opening. A conference call is scheduled for 9:00 a.m. Eastern Time the same day, with details available on the IQVIA Investor Relations website. The earnings release and financial information will also be posted online. Participants need to register in advance to join the call. IQVIA is a global leader in advanced analytics and clinical research services, employing around 74,000 people across more than 100 countries.